ワクチンアジュバント市場：製品（粒子、エマルジョン、病原体、サポニン）、投与経路（皮下、筋肉内）、疾患タイプ（感染症、癌）、用途（研究、商業）、用途分類別 - 2027年までの世界予測

Vaccine Adjuvants Market by Product (Particulate, Emulsions, Pathogen, Saponin), Route of Administration (Subcutaneous, Intramuscular), Disease Type (Infectious, Cancer), Application (Research, Commercial) & Application Category - Global Forecast to 2027

ワクチンアジュバント市場は、2022年の15億米ドルから2027年には16億米ドルに達し、予測期間中に1.7%のCAGRで推移すると予測されます。市場の成長は、感染症の有病率の上昇、開発パイプラインにおけるCOVID-19ワ... もっと見る

出版社	出版年月	電子版価格	ページ数	図表数	言語
MarketsandMarkets マーケッツアンドマーケッツ	2022年8月31日	US$4,950 シングルユーザライセンスライセンス・価格情報注文方法はこちら	206	235	英語

日本語のページは自動翻訳を利用し作成しています。

サマリー

ワクチンアジュバント市場は、2022年の15億米ドルから2027年には16億米ドルに達し、予測期間中に1.7%のCAGRで推移すると予測されます。市場の成長は、感染症の有病率の上昇、開発パイプラインにおけるCOVID-19ワクチンの増加、予防接種プログラムへの注目の高まりなどの要因によって推進されると予測されます。
2021年のワクチンアジュバント市場では、アジュバントエマルジョンが製品セグメントの最大シェアを占めています。
アジュバントエマルションは、注射部位に抗原を捕捉できるデポを生成することで機能します。その結果、免疫系への刺激を継続させるための徐放が可能となります。2021年の市場では、アジュバントエマルジョンセグメントが最大のシェアを占めています。COVID-19などの感染症におけるアジュバント乳剤の広範な使用と、感染症の有病率の上昇が、予測期間中のアジュバント乳剤セグメントの成長を促進しています。
2021年のワクチンアジュバント市場における疾患タイプ別セグメントでは、感染症セグメントが最大のシェアを占めています。
感染症セグメントは、2021年の市場で最大のシェアを占めています。このセグメントの大きなシェアは、感染症の有病率の増加や新しいアジュバントワクチンに対する需要の高まりに起因していると考えられます。
ワクチンアジュバント市場の主要プレイヤーは以下の通りです。世界のワクチンアジュバント市場における主要プレイヤーは、GSK plc（英国）、Dynavax Technologies（米国）、Novavax（米国）、Agenus Inc.(米国）、Croda International plc（英国）、Seppic（フランス）、OZ Biosciences（米国）、Phibro Animal Health Corporation（米国）、Associated British Foods plc（英国）、InvivoGen（米国）、Merck KGaA（ドイツ）、CSL Limited（オーストラリア）、Vertellus（米国）、Allergy Therapeutics（英国）、Riboxx GmbH（ドイツ）、CaPtivat＿3F5 Pharmaceuticals LLC（米国）、EuBiologics Co,Ltd.(韓国)、Pacific GeneTech Limited (米国)、Hawaii Biotech Inc. (米国)、Vaxine Pty Ltd. (オーストラリア)(オーストラリア)の5社です。

"アジア太平洋地域ワクチンアジュバント市場で最も成長率の高い地域"
アジア太平洋地域は、ライフサイエンス分野への投資の増加や、会議やシンポジウムを通じた認知度の上昇により、市場の中で最も急成長している地域と推定されます。この地域では、中国と日本が最大の市場であり、インドが予測期間中に最も高いCAGRで成長すると予測されています。

本レポートのために実施した主なインタビューは、以下のように分類されます。

- 回答者別供給側：80％、需要側：20
- 役職別マネージャー - 45%、CXOとディレクターレベル - 30%、エグゼクティブ - 25
- 地域別北米：20％、欧州：10％、アジア太平洋：55％、RoW：15

報告書に掲載された企業一覧
- GSK plc (イギリス)
- ダイナバックス・テクノロジーズ（米国）
- ノババックス（米国）
- アジェナス社（米国）
- クロダ・インターナショナル plc（イギリス）
- セピック（フランス）
- OZバイオサイエンシズ（米）
- ファイブロアニマルヘルスコーポレーション（米）
- アソシエイテッド・ブリティッシュ・フーズ plc（英国）
- インビボジェン（米）
- メルクKGaA（ドイツ）
- CSL Limited（オーストラリア）
- Vertellus（米国）
- アレルギー・セラピューティック社（英国）
- Riboxx GmbH（ドイツ）
- CaPtivatϵ Pharmaceuticals LLC（米国）
- EuBiologics Co.(韓国)
- Pacific GeneTech Limited（米国）
- ハワイバイオテック社（米国）
- Vaxine Pty Ltd.(オーストラリア)
- クリエイティブ・ダイアグノスティックス（米国）
- ライトバックスBV（オランダ）
- ムクタ・インダストリーズ（インド）
- オンコビア社(米国)
- タイターマックスUSA社(米国)

調査対象
本レポートでは、ワクチンアジュバント市場の詳細な実態を把握することができます。製品、機能、製剤、地域など、さまざまなセグメントにわたる市場規模と将来の成長可能性を推定することを目的としています。また、主要な市場プレイヤーの企業プロファイルや最近の開発状況、主要な市場戦略とともに、詳細な競合分析も掲載しています。
レポート購入の主なメリット
本レポートは、ワクチンアジュバント市場全体とそのサブセグメントに関する収益数の最も近い概算を提供することで、市場リーダー/新規参入者を支援するものです。また、利害関係者が競争環境をよりよく理解し、自社のビジネスをよりよく位置づけ、適切な市場参入戦略を立てるためのより多くの洞察を得るのに役立ちます。本レポートは、利害関係者が市場の脈動を理解し、主要な市場促進要因、阻害要因、課題、機会に関する情報を提供することを可能にします。

ページTOPに戻る

1 INTRODUCTION 30
1.1 STUDY OBJECTIVES 30
1.2 MARKET DEFINITION 30
1.2.1 INCLUSIONS AND EXCLUSIONS 31
1.3 MARKET SCOPE 31
1.3.1 MARKETS COVERED 31
1.3.2 YEARS CONSIDERED 32
1.4 CURRENCY 32
1.5 LIMITATIONS 32
1.6 STAKEHOLDERS 33
1.7 SUMMARY OF CHANGES 33
2 RESEARCH METHODOLOGY 35
2.1 RESEARCH APPROACH 35
FIGURE 1 RESEARCH DESIGN 35
2.1.1 PRIMARY RESEARCH 36
FIGURE 2 VACCINE ADJUVANTS MARKET: PRIMARY RESPONDENTS 36
2.2 MARKET ESTIMATION METHODOLOGY 37
FIGURE 3 VACCINE ADJUVANTS MARKET SIZE ESTIMATION (SUPPLY-SIDE ANALYSIS), 2021 37
FIGURE 4 MARKET SIZE ESTIMATION: APPROACH 1 (COMPANY REVENUE ANALYSIS-BASED ESTIMATION), 2021 38
2.2.1 INSIGHTS FROM PRIMARY EXPERTS 39
FIGURE 5 MARKET SIZE VALIDATION FROM PRIMARY SOURCES 39
2.3 MARKET GROWTH RATE PROJECTIONS 40
FIGURE 6 VACCINE ADJUVANTS MARKET (DEMAND SIDE): GROWTH ANALYSIS OF DEMAND-SIDE FACTORS 41
2.4 DATA TRIANGULATION 42
FIGURE 7 DATA TRIANGULATION METHODOLOGY 42
2.5 RESEARCH ASSUMPTIONS 43
2.6 RISK ANALYSIS 43
3 EXECUTIVE SUMMARY 44
FIGURE 8 VACCINE ADJUVANTS MARKET, BY PRODUCT, 2022 VS. 2027 (USD MILLION) 44
FIGURE 9 VACCINE ADJUVANTS MARKET, BY ROUTE OF ADMINISTRATION,
2022 VS. 2027 (USD MILLION) 45
FIGURE 10 VACCINE ADJUVANTS MARKET, BY DISEASE TYPE,
2022 VS. 2027 (USD MILLION) 45
FIGURE 11 VACCINE ADJUVANTS MARKET, BY APPLICATION,
2022 VS. 2027 (USD MILLION) 46
FIGURE 12 VACCINE ADJUVANTS MARKET, BY APPLICATION CATEGORY,
2022 VS. 2027 (USD MILLION) 46
FIGURE 13 GEOGRAPHICAL SNAPSHOT OF VACCINE ADJUVANTS MARKET 47
4 PREMIUM INSIGHTS 48
4.1 VACCINE ADJUVANTS MARKET OVERVIEW 48
FIGURE 14 RISING PREVALENCE OF INFECTIOUS DISEASES TO DRIVE MARKET 48
4.2 NORTH AMERICA: VACCINE ADJUVANTS MARKET, BY PRODUCT AND COUNTRY (2021) 49
FIGURE 15 ADJUVANT EMULSIONS ACCOUNTED FOR LARGEST MARKET SHARE IN 2021 49
4.3 VACCINE ADJUVANTS MARKET SHARE, BY PRODUCT, 2022 VS. 2027 50
FIGURE 16 ADJUVANT EMULSIONS SEGMENT WILL CONTINUE TO DOMINATE MARKET IN 2027 50
4.4 VACCINE ADJUVANTS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 50
FIGURE 17 CHINA TO REGISTER HIGHEST GROWTH DURING FORECAST PERIOD 50
5 MARKET OVERVIEW 51
5.1 INTRODUCTION 51
5.2 MARKET DYNAMICS 51
FIGURE 18 VACCINE ADJUVANTS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 51
TABLE 1 VACCINE ADJUVANTS MARKET: IMPACT ANALYSIS 52
5.2.1 DRIVERS 52
5.2.1.1 Rising prevalence of infectious diseases 52
5.2.1.2 Increasing use of adjuvants in vaccines 53
5.2.1.3 Collaborations and partnerships among market players for development of vaccine adjuvants 53
5.2.1.4 Increasing number of COVID-19 vaccines in development pipeline 53
FIGURE 19 TOP LOCATIONS BASED ON NUMBER OF COVID-19 VACCINES IN DEVELOPMENT PIPELINE (AS OF OCTOBER 2021) 54
5.2.1.5 Increasing focus on immunization programs 54
5.2.2 RESTRAINTS 54
5.2.2.1 Skepticism about animal-sourced vaccine adjuvants and limitations on shark fishing 54
5.2.3 OPPORTUNITIES 55
5.2.3.1 Rising funding for vaccines and infectious disease research activities 55
TABLE 2 NIH FUNDING FOR VACCINE RESEARCH, 2018–2022 (USD MILLION) 55
5.2.3.2 Development of plant-based vaccine adjuvants 55
5.2.4 CHALLENGES 56
5.2.4.1 Side effects and high toxicity of adjuvants 56
5.3 RANGES/SCENARIOS 56
FIGURE 20 SCENARIOS BASED ON IMPACT OF UNCERTAINTIES ON GROWTH OF VACCINE ADJUVANTS MARKET 56
5.4 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 57
FIGURE 21 REVENUE SHIFT AND NEW REVENUE POCKETS FOR VACCINE ADJUVANT PROVIDERS 57
5.5 PRICING ANALYSIS 57
5.5.1 AVERAGE SELLING PRICE OF PRODUCTS OFFERED BY MARKET PLAYERS 57
TABLE 3 AVERAGE SELLING PRICE OF PRODUCTS OFFERED BY MARKET PLAYERS 57
5.5.2 AVERAGE SELLING PRICE TREND 58
5.6 TECHNOLOGY ANALYSIS 58
5.6.1 SUPERCRITICAL FLUID EXTRACTION TECHNOLOGY 58
5.7 VALUE CHAIN ANALYSIS 59
FIGURE 22 VALUE CHAIN ANALYSIS 59
5.8 ECOSYSTEM ANALYSIS 60
FIGURE 23 ECOSYSTEM ANALYSIS 60
TABLE 4 SUPPLY CHAIN ECOSYSTEM 60
5.9 PATENT ANALYSIS 61
FIGURE 24 PATENT APPLICATIONS RELATED TO VACCINE ADJUVANTS MARKET, JANUARY 2012–AUGUST 2022 61
5.10 KEY CONFERENCES AND EVENTS IN 2022–2023 62
TABLE 5 LIST OF CONFERENCES AND EVENTS IN VACCINE ADJUVANTS MARKET 62
5.11 REGULATORY ANALYSIS 63
5.11.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS IN DIFFERENT REGIONS/COUNTRIES 63
5.12 PORTER’S FIVE FORCES ANALYSIS 64
TABLE 6 PORTER’S FIVE FORCES ANALYSIS 64
5.12.1 THREAT OF NEW ENTRANTS 64
5.12.2 THREAT OF SUBSTITUTES 65
5.12.3 BARGAINING POWER OF BUYERS 65
5.12.4 BARGAINING POWER OF SUPPLIERS 65
5.12.5 DEGREE OF COMPETITION 65
5.13 KEY STAKEHOLDERS AND BUYING CRITERIA 66
5.13.1 KEY STAKEHOLDERS IN PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES AND THEIR INFLUENCE ON BUYING PROCESS 66
FIGURE 25 INFLUENCE OF STAKEHOLDERS IN PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES ON BUYING PROCESS OF VACCINE ADJUVANTS 66
5.13.2 BUYING CRITERIA FOR VACCINE ADJUVANTS 66
FIGURE 26 BUYING CRITERIA FOR VACCINE ADJUVANTS 66
6 VACCINE ADJUVANTS MARKET, BY PRODUCT 67
6.1 INTRODUCTION 68
TABLE 7 VACCINE ADJUVANTS MARKET, BY PRODUCT, 2020–2027 (USD MILLION) 68
6.2 ADJUVANT EMULSIONS 68
6.2.1 ADJUVANT EMULSIONS FUNCTION BY GENERATING DEPOTS THAT TRAP ANTIGENS AT INJECTION SITE 68
TABLE 8 ADJUVANT EMULSIONS MARKET, BY REGION, 2020–2027 (USD MILLION) 69
TABLE 9 NORTH AMERICA: ADJUVANT EMULSIONS MARKET, BY COUNTRY,
2020–2027 (USD MILLION) 69
TABLE 10 EUROPE: ADJUVANT EMULSIONS MARKET, BY COUNTRY,
2020–2027 (USD MILLION) 70
TABLE 11 ASIA PACIFIC: ADJUVANT EMULSIONS MARKET, BY COUNTRY,
2020–2027 (USD MILLION) 70
6.3 PATHOGEN COMPONENTS 70
6.3.1 PROMINENT MARKET PLAYERS DEVELOPING BACTERIA-DERIVED ADJUVANTS—KEY FACTOR SUPPORTING MARKET GROWTH 70
TABLE 12 PATHOGEN COMPONENTS MARKET, BY REGION, 2020–2027 (USD MILLION) 71
TABLE 13 NORTH AMERICA: PATHOGEN COMPONENTS MARKET, BY COUNTRY,
2020–2027 (USD MILLION) 71
TABLE 14 EUROPE: PATHOGEN COMPONENTS MARKET, BY COUNTRY,
2020–2027 (USD MILLION) 72
TABLE 15 ASIA PACIFIC: PATHOGEN COMPONENTS MARKET, BY COUNTRY,
2020–2027 (USD MILLION) 72
6.4 SAPONIN-BASED ADJUVANTS 73
6.4.1 GROWING DEMAND FOR SAPONIN-BASED ADJUVANTS TO DRIVE MARKET 73
TABLE 16 SAPONIN-BASED ADJUVANTS MARKET, BY REGION,
2020–2027 (USD MILLION) 73
TABLE 17 NORTH AMERICA: SAPONIN-BASED ADJUVANTS MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 74
TABLE 18 EUROPE: SAPONIN-BASED ADJUVANTS MARKET, BY COUNTRY,
2020–2027 (USD MILLION) 74
TABLE 19 ASIA PACIFIC: SAPONIN-BASED ADJUVANTS MARKET, BY COUNTRY,
2020–2027 (USD MILLION) 74
6.5 PARTICULATE ADJUVANTS 75
6.5.1 MINERAL-BASED ADJUVANTS MOST WIDELY USED AMONG PARTICULATE ADJUVANTS 75
TABLE 20 PARTICULATE ADJUVANTS MARKET, BY REGION, 2020–2027 (USD MILLION) 75
TABLE 21 NORTH AMERICA: PARTICULATE ADJUVANTS MARKET, BY COUNTRY,
2020–2027 (USD MILLION) 76
TABLE 22 EUROPE: PARTICULATE ADJUVANTS MARKET, BY COUNTRY,
2020–2027 (USD MILLION) 76
TABLE 23 ASIA PACIFIC: PARTICULATE ADJUVANTS MARKET, BY COUNTRY,
2020–2027 (USD MILLION) 76
6.6 OTHER ADJUVANTS 77
TABLE 24 OTHER VACCINE ADJUVANTS MARKET, BY REGION,
2020–2027 (USD MILLION) 77
TABLE 25 NORTH AMERICA: OTHER VACCINE ADJUVANTS MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 77
TABLE 26 EUROPE: OTHER VACCINE ADJUVANTS MARKET, BY COUNTRY,
2020–2027 (USD MILLION) 78
TABLE 27 ASIA PACIFIC: OTHER VACCINE ADJUVANTS MARKET, BY COUNTRY,
2020–2027 (USD MILLION) 78

7 VACCINE ADJUVANTS MARKET, BY ROUTE OF ADMINISTRATION 79
7.1 INTRODUCTION 80
TABLE 28 VACCINE ADJUVANTS MARKET, BY ROUTE OF ADMINISTRATION,
2020–2027 (USD MILLION) 80
7.2 INTRAMUSCULAR 80
7.2.1 LARGEST AND FASTEST-GROWING MARKET SEGMENT 80
TABLE 29 ADVANTAGES AND DISADVANTAGES OF INTRAMUSCULAR ADMINISTRATION 81
TABLE 30 VACCINE ADJUVANTS MARKET FOR INTRAMUSCULAR ADMINISTRATION,
BY REGION, 2020–2027 (USD MILLION) 81
TABLE 31 NORTH AMERICA: VACCINE ADJUVANTS MARKET FOR INTRAMUSCULAR ADMINISTRATION, BY COUNTRY, 2020–2027 (USD MILLION) 81
TABLE 32 EUROPE: VACCINE ADJUVANTS MARKET FOR INTRAMUSCULAR ADMINISTRATION, BY COUNTRY, 2020–2027 (USD MILLION) 82
TABLE 33 ASIA PACIFIC: VACCINE ADJUVANTS MARKET FOR INTRAMUSCULAR ADMINISTRATION, BY COUNTRY, 2020–2027 (USD MILLION) 82
7.3 SUBCUTANEOUS 83
7.3.1 ADVANTAGES OFFERED BY SUBCUTANEOUS ADMINISTRATION TO DRIVE MARKET 83
TABLE 34 ADVANTAGES AND DISADVANTAGES OF SUBCUTANEOUS ADMINISTRATION 83
TABLE 35 VACCINE ADJUVANTS MARKET FOR SUBCUTANEOUS ADMINISTRATION,
BY REGION, 2020–2027 (USD MILLION) 83
TABLE 36 NORTH AMERICA: VACCINE ADJUVANTS MARKET FOR SUBCUTANEOUS ADMINISTRATION, BY COUNTRY, 2020–2027 (USD MILLION) 84
TABLE 37 EUROPE: VACCINE ADJUVANTS MARKET FOR SUBCUTANEOUS ADMINISTRATION, BY COUNTRY, 2020–2027 (USD MILLION) 84
TABLE 38 ASIA PACIFIC: VACCINE ADJUVANTS MARKET FOR SUBCUTANEOUS ADMINISTRATION, BY COUNTRY, 2020–2027 (USD MILLION) 84
7.4 OTHER ROUTES OF ADMINISTRATION 85
TABLE 39 VACCINE ADJUVANTS MARKET FOR OTHER ROUTES OF ADMINISTRATION,
BY REGION, 2020–2027 (USD MILLION) 85
TABLE 40 NORTH AMERICA: VACCINE ADJUVANTS MARKET FOR OTHER ROUTES OF ADMINISTRATION, BY COUNTRY, 2020–2027 (USD MILLION) 85
TABLE 41 EUROPE: VACCINE ADJUVANTS MARKET FOR OTHER ROUTES OF ADMINISTRATION, BY COUNTRY, 2020–2027 (USD MILLION) 86
TABLE 42 ASIA PACIFIC: VACCINE ADJUVANTS MARKET FOR OTHER ROUTES OF ADMINISTRATION, BY COUNTRY, 2020–2027 (USD MILLION) 86
8 VACCINE ADJUVANTS MARKET, BY DISEASE TYPE 87
8.1 INTRODUCTION 88
TABLE 43 VACCINE ADJUVANTS MARKET, BY DISEASE TYPE,
2020–2027 (USD MILLION) 88
8.2 INFECTIOUS DISEASES 88
8.2.1 INCREASED PREVALENCE OF INFECTIOUS DISEASES TO DRIVE MARKET 88
TABLE 44 VACCINE ADJUVANTS MARKET FOR INFECTIOUS DISEASES, BY REGION, 2020–2027 (USD MILLION) 89
TABLE 45 NORTH AMERICA: VACCINE ADJUVANTS MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2020–2027 (USD MILLION) 90
TABLE 46 EUROPE: VACCINE ADJUVANTS MARKET FOR INFECTIOUS DISEASES,
BY COUNTRY, 2020–2027 (USD MILLION) 90
TABLE 47 ASIA PACIFIC: VACCINE ADJUVANTS MARKET FOR INFECTIOUS DISEASES,
BY COUNTRY, 2020–2027 (USD MILLION) 90
8.3 CANCER 91
8.3.1 INCREASING DEMAND FOR NOVEL CANCER VACCINES TO SUPPORT MARKET GROWTH 91
TABLE 48 VACCINE ADJUVANTS MARKET FOR CANCER, BY REGION,
2020–2027 (USD MILLION) 91
TABLE 49 NORTH AMERICA: VACCINE ADJUVANTS MARKET FOR CANCER, BY COUNTRY, 2020–2027 (USD MILLION) 91
TABLE 50 EUROPE: VACCINE ADJUVANTS MARKET FOR CANCER, BY COUNTRY,
2020–2027 (USD MILLION) 92
TABLE 51 ASIA PACIFIC: VACCINE ADJUVANTS MARKET FOR CANCER, BY COUNTRY, 2020–2027 (USD MILLION) 92
8.4 OTHER DISEASES 93
TABLE 52 VACCINE ADJUVANTS MARKET FOR OTHER DISEASES, BY REGION,
2020–2027 (USD MILLION) 93
TABLE 53 NORTH AMERICA: VACCINE ADJUVANTS MARKET FOR OTHER DISEASES,
BY COUNTRY, 2020–2027 (USD MILLION) 93
TABLE 54 EUROPE: VACCINE ADJUVANTS MARKET FOR OTHER DISEASES, BY COUNTRY, 2020–2027 (USD MILLION) 94
TABLE 55 ASIA PACIFIC: VACCINE ADJUVANTS MARKET FOR OTHER DISEASES,
BY COUNTRY, 2020–2027 (USD MILLION) 94
9 VACCINE ADJUVANTS MARKET, BY APPLICATION 95
9.1 INTRODUCTION 96
TABLE 56 VACCINE ADJUVANTS MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 96
9.2 RESEARCH APPLICATIONS 96
9.2.1 EXTENSIVE R&D FOR DEVELOPMENT OF VACCINE ADJUVANTS TO DRIVE MARKET 96
TABLE 57 VACCINE ADJUVANTS MARKET FOR RESEARCH APPLICATIONS, BY REGION, 2020–2027 (USD MILLION) 97
TABLE 58 NORTH AMERICA: VACCINE ADJUVANTS MARKET FOR RESEARCH APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION) 97
TABLE 59 EUROPE: VACCINE ADJUVANTS MARKET FOR RESEARCH APPLICATIONS,
BY COUNTRY, 2020–2027 (USD MILLION) 98
TABLE 60 ASIA PACIFIC: VACCINE ADJUVANTS MARKET FOR RESEARCH APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION) 98
9.3 COMMERCIAL APPLICATIONS 98
9.3.1 GROWING USE OF VACCINE ADJUVANTS FOR COMMERCIAL APPLICATIONS TO SUPPORT MARKET GROWTH 98
TABLE 61 VACCINE ADJUVANTS MARKET FOR COMMERCIAL APPLICATIONS,
BY REGION, 2020–2027 (USD MILLION) 99
TABLE 62 NORTH AMERICA: VACCINE ADJUVANTS MARKET FOR COMMERCIAL APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION) 99
TABLE 63 EUROPE: VACCINE ADJUVANTS MARKET FOR COMMERCIAL APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION) 100
TABLE 64 ASIA PACIFIC: VACCINE ADJUVANTS MARKET FOR COMMERCIAL APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION) 100
10 VACCINE ADJUVANTS MARKET, BY APPLICATION CATEGORY 101
10.1 INTRODUCTION 102
TABLE 65 VACCINE ADJUVANTS MARKET, BY APPLICATION CATEGORY,
2020–2027 (USD MILLION) 102
10.2 HUMAN VACCINE ADJUVANTS 102
10.2.1 INCREASE IN PARTNERSHIPS FOR DEVELOPMENT OF HUMAN VACCINE ADJUVANTS 102
TABLE 66 HUMAN VACCINE ADJUVANTS MARKET, BY REGION,
2020–2027 (USD MILLION) 103
TABLE 67 NORTH AMERICA: HUMAN VACCINE ADJUVANTS MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 103
TABLE 68 EUROPE: HUMAN VACCINE ADJUVANTS MARKET, BY COUNTRY,
2020–2027 (USD MILLION) 103
TABLE 69 ASIA PACIFIC: HUMAN VACCINE ADJUVANTS MARKET, BY COUNTRY,
2020–2027 (USD MILLION) 104
10.3 VETERINARY VACCINE ADJUVANTS 104
10.3.1 DEVELOPMENT OF ANIMAL VACCINES GOVERNED BY FEWER REGULATORY ASPECTS 104
TABLE 70 VETERINARY VACCINE ADJUVANTS MARKET, BY REGION,
2020–2027 (USD MILLION) 105
TABLE 71 NORTH AMERICA: VETERINARY VACCINE ADJUVANTS MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 105
TABLE 72 EUROPE: VETERINARY VACCINE ADJUVANTS MARKET, BY COUNTRY,
2020–2027 (USD MILLION) 105
TABLE 73 ASIA PACIFIC: VETERINARY VACCINE ADJUVANTS MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 106
11 VACCINE ADJUVANTS MARKET, BY REGION 107
11.1 INTRODUCTION 108
TABLE 74 VACCINE ADJUVANTS MARKET, BY REGION, 2020–2027 (USD MILLION) 108
11.2 NORTH AMERICA 108
FIGURE 27 NORTH AMERICA: VACCINE ADJUVANTS MARKET SNAPSHOT 109
TABLE 75 NORTH AMERICA: VACCINE ADJUVANTS MARKET, BY COUNTRY,
2020–2027 (USD MILLION) 110
TABLE 76 NORTH AMERICA: VACCINE ADJUVANTS MARKET, BY PRODUCT,
2020–2027 (USD MILLION) 110
TABLE 77 NORTH AMERICA: VACCINE ADJUVANTS MARKET,
BY ROUTE OF ADMINISTRATION, 2020–2027 (USD MILLION) 110
TABLE 78 NORTH AMERICA: VACCINE ADJUVANTS MARKET, BY DISEASE TYPE,
2020–2027 (USD MILLION) 111
TABLE 79 NORTH AMERICA: VACCINE ADJUVANTS MARKET, BY APPLICATION,
2020–2027 (USD MILLION) 111
TABLE 80 NORTH AMERICA: VACCINE ADJUVANTS MARKET, BY APPLICATION CATEGORY, 2020–2027 (USD MILLION) 111

11.2.1 US 112
11.2.1.1 US dominates North American vaccine adjuvants market 112
TABLE 81 US: VACCINE ADJUVANTS MARKET, BY PRODUCT,
2020–2027 (USD MILLION) 113
TABLE 82 US: VACCINE ADJUVANTS MARKET, BY ROUTE OF ADMINISTRATION,
2020–2027 (USD MILLION) 113
TABLE 83 US: VACCINE ADJUVANTS MARKET, BY DISEASE TYPE,
2020–2027 (USD MILLION) 113
TABLE 84 US: VACCINE ADJUVANTS MARKET, BY APPLICATION,
2020–2027 (USD MILLION) 114
TABLE 85 US: VACCINE ADJUVANTS MARKET, BY APPLICATION CATEGORY,
2020–2027 (USD MILLION) 114
11.2.2 CANADA 114
11.2.2.1 Increasing government funding for vaccine research to drive market 114
TABLE 86 CANADA: VACCINE ADJUVANTS MARKET, BY PRODUCT,
2020–2027 (USD MILLION) 115
TABLE 87 CANADA: VACCINE ADJUVANTS MARKET, BY ROUTE OF ADMINISTRATION, 2020–2027 (USD MILLION) 115
TABLE 88 CANADA: VACCINE ADJUVANTS MARKET, BY DISEASE TYPE,
2020–2027 (USD MILLION) 115
TABLE 89 CANADA: VACCINE ADJUVANTS MARKET, BY APPLICATION,
2020–2027 (USD MILLION) 116
TABLE 90 CANADA: VACCINE ADJUVANTS MARKET, BY APPLICATION CATEGORY,
2020–2027 (USD MILLION) 116
11.3 EUROPE 117
TABLE 91 EUROPE: VACCINE ADJUVANTS MARKET, BY COUNTRY,
2020–2027 (USD MILLION) 117
TABLE 92 EUROPE: VACCINE ADJUVANTS MARKET, BY PRODUCT,
2020–2027 (USD MILLION) 117
TABLE 93 EUROPE: VACCINE ADJUVANTS MARKET, BY ROUTE OF ADMINISTRATION, 2020–2027 (USD MILLION) 118
TABLE 94 EUROPE: VACCINE ADJUVANTS MARKET, BY DISEASE TYPE,
2020–2027 (USD MILLION) 118
TABLE 95 EUROPE: VACCINE ADJUVANTS MARKET, BY APPLICATION,
2020–2027 (USD MILLION) 118
TABLE 96 EUROPE: VACCINE ADJUVANTS MARKET, BY APPLICATION CATEGORY,
2020–2027 (USD MILLION) 119
11.3.1 GERMANY 119
11.3.1.1 Growing funding from government organizations to drive market 119
TABLE 97 GERMANY: VACCINE ADJUVANTS MARKET, BY PRODUCT,
2020–2027 (USD MILLION) 120
TABLE 98 GERMANY: VACCINE ADJUVANTS MARKET, BY ROUTE OF ADMINISTRATION, 2020–2027 (USD MILLION) 120
TABLE 99 GERMANY: VACCINE ADJUVANTS MARKET, BY DISEASE TYPE,
2020–2027 (USD MILLION) 120
TABLE 100 GERMANY: VACCINE ADJUVANTS MARKET, BY APPLICATION,
2020–2027 (USD MILLION) 121
TABLE 101 GERMANY: VACCINE ADJUVANTS MARKET, BY APPLICATION CATEGORY, 2020–2027 (USD MILLION) 121
11.3.2 UK 121
11.3.2.1 Rising investments in vaccine development to boost market growth 121
TABLE 102 UK: VACCINE ADJUVANTS MARKET, BY PRODUCT,
2020–2027 (USD MILLION) 122
TABLE 103 UK: VACCINE ADJUVANTS MARKET, BY ROUTE OF ADMINISTRATION,
2020–2027 (USD MILLION) 122
TABLE 104 UK: VACCINE ADJUVANTS MARKET, BY DISEASE TYPE,
2020–2027 (USD MILLION) 123
TABLE 105 UK: VACCINE ADJUVANTS MARKET, BY APPLICATION,
2020–2027 (USD MILLION) 123
TABLE 106 UK: VACCINE ADJUVANTS MARKET, BY APPLICATION CATEGORY,
2020–2027 (USD MILLION) 123
11.3.3 FRANCE 124
11.3.3.1 Focus on new vaccine development to drive market 124
TABLE 107 FRANCE: VACCINE ADJUVANTS MARKET, BY PRODUCT,
2020–2027 (USD MILLION) 124
TABLE 108 FRANCE: VACCINE ADJUVANTS MARKET, BY ROUTE OF ADMINISTRATION, 2020–2027 (USD MILLION) 125
TABLE 109 FRANCE: VACCINE ADJUVANTS MARKET, BY DISEASE TYPE,
2020–2027 (USD MILLION) 125
TABLE 110 FRANCE: VACCINE ADJUVANTS MARKET, BY APPLICATION,
2020–2027 (USD MILLION) 125
TABLE 111 FRANCE: VACCINE ADJUVANTS MARKET, BY APPLICATION CATEGORY,
2020–2027 (USD MILLION) 126
11.3.4 ITALY 126
11.3.4.1 Increase in R&D for vaccines and government initiatives—key factors driving market 126
TABLE 112 ITALY: VACCINE ADJUVANTS MARKET, BY PRODUCT,
2020–2027 (USD MILLION) 126
TABLE 113 ITALY: VACCINE ADJUVANTS MARKET, BY ROUTE OF ADMINISTRATION,
2020–2027 (USD MILLION) 127
TABLE 114 ITALY: VACCINE ADJUVANTS MARKET, BY DISEASE TYPE,
2020–2027 (USD MILLION) 127
TABLE 115 ITALY: VACCINE ADJUVANTS MARKET, BY APPLICATION,
2020–2027 (USD MILLION) 127
TABLE 116 ITALY: VACCINE ADJUVANTS MARKET, BY APPLICATION CATEGORY,
2020–2027 (USD MILLION) 128
11.3.5 SPAIN 128
11.3.5.1 Increasing investments in vaccine development by government and private organizations to drive market 128
TABLE 117 SPAIN: VACCINE ADJUVANTS MARKET, BY PRODUCT,
2020–2027 (USD MILLION) 129
TABLE 118 SPAIN: VACCINE ADJUVANTS MARKET, BY ROUTE OF ADMINISTRATION, 2020–2027 (USD MILLION) 129
TABLE 119 SPAIN: VACCINE ADJUVANTS MARKET, BY DISEASE TYPE,
2020–2027 (USD MILLION) 129
TABLE 120 SPAIN: VACCINE ADJUVANTS MARKET, BY APPLICATION,
2020–2027 (USD MILLION) 130
TABLE 121 SPAIN: VACCINE ADJUVANTS MARKET, BY APPLICATION CATEGORY,
2020–2027 (USD MILLION) 130
11.3.6 REST OF EUROPE 130
TABLE 122 REST OF EUROPE: VACCINE ADJUVANTS MARKET, BY PRODUCT,
2020–2027 (USD MILLION) 131
TABLE 123 REST OF EUROPE: VACCINE ADJUVANTS MARKET,
BY ROUTE OF ADMINISTRATION, 2020–2027 (USD MILLION) 131
TABLE 124 REST OF EUROPE: VACCINE ADJUVANTS MARKET, BY DISEASE TYPE,
2020–2027 (USD MILLION) 131
TABLE 125 REST OF EUROPE: VACCINE ADJUVANTS MARKET, BY APPLICATION,
2020–2027 (USD MILLION) 132
TABLE 126 REST OF EUROPE: VACCINE ADJUVANTS MARKET, BY APPLICATION CATEGORY, 2020–2027 (USD MILLION) 132
11.4 ASIA PACIFIC 132
FIGURE 28 ASIA PACIFIC: VACCINE ADJUVANTS MARKET SNAPSHOT 133
TABLE 127 ASIA PACIFIC: VACCINE ADJUVANTS MARKET, BY COUNTRY,
2020–2027 (USD MILLION) 134
TABLE 128 ASIA PACIFIC: VACCINE ADJUVANTS MARKET, BY PRODUCT,
2020–2027 (USD MILLION) 134
TABLE 129 ASIA PACIFIC: VACCINE ADJUVANTS MARKET,
BY ROUTE OF ADMINISTRATION, 2020–2027 (USD MILLION) 134
TABLE 130 ASIA PACIFIC: VACCINE ADJUVANTS MARKET, BY DISEASE TYPE,
2020–2027 (USD MILLION) 135
TABLE 131 ASIA PACIFIC: VACCINE ADJUVANTS MARKET, BY APPLICATION,
2020–2027 (USD MILLION) 135
TABLE 132 ASIA PACIFIC: VACCINE ADJUVANTS MARKET, BY APPLICATION CATEGORY, 2020–2027 (USD MILLION) 135
11.4.1 CHINA 136
11.4.1.1 Government support and strategic initiatives by key players to strengthen biotechnology sector 136
TABLE 133 CHINA: VACCINE ADJUVANTS MARKET, BY PRODUCT,
2020–2027 (USD MILLION) 136
TABLE 134 CHINA: VACCINE ADJUVANTS MARKET, BY ROUTE OF ADMINISTRATION, 2020–2027 (USD MILLION) 137
TABLE 135 CHINA: VACCINE ADJUVANTS MARKET, BY DISEASE TYPE,
2020–2027 (USD MILLION) 137
TABLE 136 CHINA: VACCINE ADJUVANTS MARKET, BY APPLICATION,
2020–2027 (USD MILLION) 137
TABLE 137 CHINA: VACCINE ADJUVANTS MARKET, BY APPLICATION CATEGORY,
2020–2027 (USD MILLION) 138
11.4.2 JAPAN 138
11.4.2.1 Government initiatives for vaccines to boost market 138
TABLE 138 JAPAN: VACCINE ADJUVANTS MARKET, BY PRODUCT,
2020–2027 (USD MILLION) 138
TABLE 139 JAPAN: VACCINE ADJUVANTS MARKET, BY ROUTE OF ADMINISTRATION, 2020–2027 (USD MILLION) 139
TABLE 140 JAPAN: VACCINE ADJUVANTS MARKET, BY DISEASE TYPE,
2020–2027 (USD MILLION) 139
TABLE 141 JAPAN: VACCINE ADJUVANTS MARKET, BY APPLICATION,
2020–2027 (USD MILLION) 139
TABLE 142 JAPAN: VACCINE ADJUVANTS MARKET, BY APPLICATION CATEGORY,
2020–2027 (USD MILLION) 140
11.4.3 INDIA 140
11.4.3.1 Growth of the biotechnology sector and development of new vaccines to drive market 140
TABLE 143 INDIA: VACCINE ADJUVANTS MARKET, BY PRODUCT,
2020–2027 (USD MILLION) 140
TABLE 144 INDIA: VACCINE ADJUVANTS MARKET, BY ROUTE OF ADMINISTRATION, 2020–2027 (USD MILLION) 141
TABLE 145 INDIA: VACCINE ADJUVANTS MARKET, BY DISEASE TYPE,
2020–2027 (USD MILLION) 141
TABLE 146 INDIA: VACCINE ADJUVANTS MARKET, BY APPLICATION,
2020–2027 (USD MILLION) 141
TABLE 147 INDIA: VACCINE ADJUVANTS MARKET, BY APPLICATION CATEGORY,
2020–2027 (USD MILLION) 142
11.4.4 REST OF ASIA PACIFIC 142
TABLE 148 REST OF ASIA PACIFIC: VACCINE ADJUVANTS MARKET, BY PRODUCT,
2020–2027 (USD MILLION) 142
TABLE 149 REST OF ASIA PACIFIC: VACCINE ADJUVANTS MARKET,
BY ROUTE OF ADMINISTRATION, 2020–2027 (USD MILLION) 143
TABLE 150 REST OF ASIA PACIFIC: VACCINE ADJUVANTS MARKET, BY DISEASE TYPE, 2020–2027 (USD MILLION) 143
TABLE 151 REST OF ASIA PACIFIC: VACCINE ADJUVANTS MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 143
TABLE 152 REST OF ASIA PACIFIC: VACCINE ADJUVANTS MARKET, BY APPLICATION CATEGORY, 2020–2027 (USD MILLION) 144
11.5 LATIN AMERICA 144
11.5.1 SURGE IN PHARMACEUTICAL AND BIOTECHNOLOGY RESEARCH—
KEY FACTOR DRIVING MARKET 144
TABLE 153 LATIN AMERICA: VACCINE ADJUVANTS MARKET, BY PRODUCT,
2020–2027 (USD MILLION) 144
TABLE 154 LATIN AMERICA: VACCINE ADJUVANTS MARKET,
BY ROUTE OF ADMINISTRATION, 2020–2027 (USD MILLION) 145
TABLE 155 LATIN AMERICA: VACCINE ADJUVANTS MARKET, BY DISEASE TYPE,
2020–2027 (USD MILLION) 145
TABLE 156 LATIN AMERICA: VACCINE ADJUVANTS MARKET, BY APPLICATION,
2020–2027 (USD MILLION) 145
TABLE 157 LATIN AMERICA: VACCINE ADJUVANTS MARKET, BY APPLICATION CATEGORY, 2020–2027 (USD MILLION) 146
11.6 MIDDLE EAST AND AFRICA 146
11.6.1 INCREASING FUNDING AND GRANTS FOR VACCINE DEVELOPMENT TO DRIVE MARKET 146
TABLE 158 MIDDLE EAST AND AFRICA: VACCINE ADJUVANTS MARKET, BY PRODUCT, 2020–2027 (USD MILLION) 146
TABLE 159 MIDDLE EAST AND AFRICA: VACCINE ADJUVANTS MARKET,
BY ROUTE OF ADMINISTRATION, 2020–2027 (USD MILLION) 147
TABLE 160 MIDDLE EAST AND AFRICA: VACCINE ADJUVANTS MARKET, BY DISEASE TYPE, 2020–2027 (USD MILLION) 147
TABLE 161 MIDDLE EAST AND AFRICA: VACCINE ADJUVANTS MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 147
TABLE 162 MIDDLE EAST AND AFRICA: VACCINE ADJUVANTS MARKET, BY APPLICATION CATEGORY, 2020–2027 (USD MILLION) 148
12 COMPETITIVE LANDSCAPE 149
12.1 INTRODUCTION 149
12.2 RIGHT-TO-WIN APPROACHES ADOPTED BY KEY PLAYERS 150
FIGURE 29 VACCINE ADJUVANTS MARKET: STRATEGIES ADOPTED 150
12.3 MARKET SHARE ANALYSIS 151
FIGURE 30 VACCINE ADJUVANTS MARKET SHARE ANALYSIS, BY KEY PLAYER (2021) 151
TABLE 163 VACCINE ADJUVANTS MARKET: DEGREE OF COMPETITION 151
12.4 REVENUE ANALYSIS 152
FIGURE 31 REVENUE ANALYSIS FOR KEY COMPANIES (2019–2021) 152
12.5 COMPANY EVALUATION QUADRANT 153
12.5.1 STARS 153
12.5.2 EMERGING LEADERS 153
12.5.3 PERVASIVE PLAYERS 153
12.5.4 PARTICIPANTS 153
FIGURE 32 VACCINE ADJUVANTS MARKET: COMPANY EVALUATION MATRIX, 2021 154
12.6 COMPETITIVE BENCHMARKING OF TOP 25 PLAYERS 155
12.6.1 COMPANY FOOTPRINT (25 COMPANIES) 155
TABLE 164 PRODUCT AND REGIONAL FOOTPRINT ANALYSIS OF KEY PLAYERS IN VACCINE ADJUVANTS MARKET 155
12.6.2 COMPANY PRODUCT FOOTPRINT (25 COMPANIES) 156
TABLE 165 PRODUCT FOOTPRINT ANALYSIS OF KEY PLAYERS IN VACCINE ADJUVANTS MARKET 156
12.6.3 COMPANY REGIONAL FOOTPRINT (25 COMPANIES) 157
TABLE 166 REGIONAL FOOTPRINT ANALYSIS OF KEY PLAYERS IN VACCINE ADJUVANTS MARKET 157
12.7 COMPANY EVALUATION QUADRANT FOR STARTUPS/SMES 158
12.7.1 PROGRESSIVE COMPANIES 158
12.7.2 STARTING BLOCKS 158
12.7.3 RESPONSIVE COMPANIES 158
12.7.4 DYNAMIC COMPANIES 158
FIGURE 33 VACCINE ADJUVANTS MARKET: COMPANY EVALUATION MATRIX FOR STARTUPS/SMES, 2021 159
12.8 COMPETITIVE BENCHMARKING OF STARTUP/SME PLAYERS 160
TABLE 167 DETAILED LIST OF KEY STARTUP/SMES 160
TABLE 168 COMPETITIVE BENCHMARKING OF KEY PLAYERS (STARTUPS/SMES) 161
12.9 COMPETITIVE SCENARIO AND TRENDS 161
12.9.1 PRODUCT LAUNCHES 161
TABLE 169 KEY PRODUCT LAUNCHES, JANUARY 2019–JULY 2022 161
12.9.2 DEALS 162
TABLE 170 KEY DEALS, JANUARY 2019–JULY 2022 162
12.9.3 OTHER KEY DEVELOPMENTS 163
TABLE 171 OTHER KEY DEVELOPMENTS, JANUARY 2019–JULY 2022 163
13 COMPANY PROFILES 164
13.1 KEY PLAYERS 164
(Business Overview, Products/Services/Solutions Offered, MnM View, Key Strengths and Right to Win, Strategic Choices Made, Weaknesses and Competitive Threats, Recent Developments)*
13.1.1 GSK PLC 164
TABLE 172 GSK PLC: BUSINESS OVERVIEW 164
FIGURE 34 GSK PLC: COMPANY SNAPSHOT (2021) 165
13.1.2 DYNAVAX TECHNOLOGIES 169
TABLE 173 DYNAVAX TECHNOLOGIES: BUSINESS OVERVIEW 169
FIGURE 35 DYNAVAX TECHNOLOGIES: COMPANY SNAPSHOT (2021) 169
13.1.3 NOVAVAX 173
TABLE 174 NOVAVAX: BUSINESS OVERVIEW 173
FIGURE 36 NOVAVAX: COMPANY SNAPSHOT (2021) 173
13.1.4 AGENUS INC. 176
TABLE 175 AGENUS INC.: BUSINESS OVERVIEW 176
FIGURE 37 AGENUS INC.: COMPANY SNAPSHOT (2021) 176
13.1.5 CRODA INTERNATIONAL PLC 178
TABLE 176 CRODA INTERNATIONAL PLC: BUSINESS OVERVIEW 178
FIGURE 38 CRODA INTERNATIONAL PLC: COMPANY SNAPSHOT (2021) 179
13.1.6 SEPPIC (SUBSIDIARY OF AIR LIQUIDE GROUP) 181
TABLE 177 AIR LIQUIDE GROUP: BUSINESS OVERVIEW 181
FIGURE 39 AIR LIQUIDE: COMPANY SNAPSHOT (2021) 182
13.1.7 PHIBRO ANIMAL HEALTH CORPORATION 184
TABLE 178 PHIBRO ANIMAL HEALTH CORPORATION: BUSINESS OVERVIEW 184
FIGURE 40 PHIBRO ANIMAL HEALTH CORPORATION: COMPANY SNAPSHOT (2020) 185
13.1.8 SPI PHARMA (SUBSIDIARY OF ASSOCIATED BRITISH FOODS PLC) 186
TABLE 179 ASSOCIATED BRITISH FOODS PLC: BUSINESS OVERVIEW 186
FIGURE 41 ASSOCIATED BRITISH FOODS PLC: COMPANY SNAPSHOT (2021) 187
13.1.9 CSL LIMITED 188
TABLE 180 CSL LIMITED: BUSINESS OVERVIEW 188
FIGURE 42 CSL LIMITED: COMPANY SNAPSHOT (2021) 189
13.1.10 MERCK KGAA 191
TABLE 181 MERCK KGAA: BUSINESS OVERVIEW 191
FIGURE 43 MERCK KGAA: COMPANY SNAPSHOT (2021) 192
13.1.11 OZ BIOSCIENCES 193
TABLE 182 OZ BIOSCIENCES: BUSINESS OVERVIEW 193
13.1.12 INVIVOGEN 194
TABLE 183 INVIVOGEN: BUSINESS OVERVIEW 194
13.1.13 ALLERGY THERAPEUTICS 196
TABLE 184 ALLERGY THERAPEUTICS: BUSINESS OVERVIEW 196
FIGURE 44 ALLERGY THERAPEUTICS: COMPANY SNAPSHOT (2020) 196
13.1.14 VERTELLUS 198
TABLE 185 VERTELLUS: BUSINESS OVERVIEW 198
13.1.15 EUBIOLOGICS CO., LTD. 199
TABLE 186 EUBIOLOGICS CO., LTD.: BUSINESS OVERVIEW 199
13.1.16 PACIFIC GENETECH LIMITED 200
TABLE 187 PACIFIC GENETECH LIMITED: BUSINESS OVERVIEW 200
13.1.17 HAWAII BIOTECH INC. 201
TABLE 188 HAWAII BIOTECH INC.: BUSINESS OVERVIEW 201
13.1.18 RIBOXX GMBH 202
TABLE 189 RIBOXX GMBH: BUSINESS OVERVIEW 202
13.1.19 CAPTIVATE PHARMACEUTICALS LLC 203
TABLE 190 CAPTIVATE PHARMACEUTICALS LLC: BUSINESS OVERVIEW 203
13.1.20 VAXINE PTY LTD. 204
TABLE 191 VAXINE PTY LTD.: BUSINESS OVERVIEW 204
*Business Overview, Products/Services/Solutions Offered, MnM View, Key Strengths and Right to Win, Strategic Choices Made, Weaknesses and Competitive Threats, Recent Developments might not be captured in case of unlisted companies.
13.2 OTHER COMPANIES 205
13.2.1 CREATIVE DIAGNOSTICS 205
13.2.2 LITEVAX BV 205
13.2.3 MUKTA INDUSTRIES 206
13.2.4 ONCOVIR, INC. 206
13.2.5 TITERMAX USA, INC. 207
14 APPENDIX 208
14.1 DISCUSSION GUIDE 208
14.2 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 211
14.3 CUSTOMIZATION OPTIONS 213
14.4 RELATED REPORTS 213
14.5 AUTHOR DETAILS 214

ページTOPに戻る

Table of Contents

Summary

The vaccine adjuvants market is projected to reach USD 1.6 Billion by 2027 from USD 1.5 Billion in 2022, at a CAGR of 1.7% during the forecast period. The growth of the market is projected to be driven by factors such as the rising prevalence of infectious diseases, increasing number of COVID-19 vaccines in the development pipeline, and increasing focus on immunization programs.
The adjuvant emulsions accounted for the largest share of the product segment in the vaccine adjuvants market in 2021.
Adjuvant emulsions function by generating depots that can trap antigens at the injection site. This results in slow release to continue the stimulation of the immune system. The adjuvant emulsions segment accounted for the largest share of the market in 2021. The extensive use of adjuvant emulsions in COVID-19 and other infectious diseases and the rising prevalence of infectious diseases are driving the growth of the adjuvant emulsions segment during the forecast period.
The infectious disease segment accounted for the largest share of the disease type segment in the vaccine adjuvants market in 2021.
The infectious diseases segment accounted for the largest share of the market in 2021. The large share of this segment can be attributed to the increasing prevalence of infectious diseases and the rising demand for new adjuvanted vaccines.
Key players in the vaccine adjuvants market include Prominent players in the global vaccine adjuvants market are GSK plc (UK), Dynavax Technologies (US), Novavax (US), Agenus Inc. (US), Croda International plc (UK), Seppic (France), OZ Biosciences (US), Phibro Animal Health Corporation (US), Associated British Foods plc (UK), InvivoGen (US), Merck KGaA (Germany), CSL Limited (Australia), Vertellus (US), Allergy Therapeutics (UK), Riboxx GmbH (Germany), CaPtivatϵ Pharmaceuticals LLC (US), EuBiologics Co., Ltd. (South Korea), Pacific GeneTech Limited (US), Hawaii Biotech Inc. (US), and Vaxine Pty Ltd. (Australia).

“Asia Pacific: The fastest-growing region in the vaccine adjuvants market”
The Asia Pacific is estimated to be the fastest-growing segment of the market, owing to the increasing investments in the life sciences sector and rising awareness through conferences and symposiums. In this region, China and Japan are the largest markets while India is projected to grow at a highest CAGR during the forecast period.

The primary interviews conducted for this report can be categorized as follows:

• By Respondent: Supply Side- 80% and Demand Side - 20%
• By Designation: Managers- 45%, CXOs and Director level - 30%, and Executives - 25%
• By Region: North America -20%, Europe -10%, Asia-Pacific -55%, RoW -15%

List of Companies Profiled in the Report:
• GSK plc (UK)
• Dynavax Technologies (US)
• Novavax (US)
• Agenus Inc. (US)
• Croda International plc (UK)
• Seppic (France)
• OZ Biosciences (US)
• Phibro Animal Health Corporation (US)
• Associated British Foods plc (UK)
• InvivoGen (US)
• Merck KGaA (Germany)
• CSL Limited (Australia)
• Vertellus (US)
• Allergy Therapeutics (UK)
• Riboxx GmbH (Germany)
• CaPtivatϵ Pharmaceuticals LLC (US)
• EuBiologics Co., Ltd. (South Korea)
• Pacific GeneTech Limited (US)
• Hawaii Biotech Inc. (US)
• Vaxine Pty Ltd. (Australia)
• Creative Diagnostics (US)
• LiteVax BV (Netherlands)
• Mukta Industries (India)
• Oncovir, Inc. (US)
• TiterMax USA, Inc. (US).

Research Coverage:
This report provides a detailed picture of the vaccine adjuvants market. It aims at estimating the size and future growth potential of the market across different segments such as the product, functionality, formulation and region. The report also includes an in-depth competitive analysis of the key market players along with their company profiles recent developments and key market strategies.
Key Benefits of Buying the Report:
The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the overall vaccine adjuvants market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the market's pulse and provide them with information on the key market drivers, restraints, challenges, and opportunities.

ページTOPに戻る

ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。

webからのご注文・お問合せはこちらのフォームから承ります

本レポートと同分野（抗生物薬）の最新刊レポート

MarketsandMarkets社の抗生物薬分野での最新刊レポート

本レポートと同じKEY WORD（cancer）の最新刊レポート

よくあるご質問

MarketsandMarkets社はどのような調査会社ですか?

マーケッツアンドマーケッツ（MarketsandMarkets）は通信、半導体、医療機器、エネルギーなど、幅広い市場に関する調査レポートを出版しています。また広範な市場を対象としたカスタム調査も行って... もっと見る

調査レポートの納品までの日数はどの程度ですか?

在庫のあるものは速納となりますが、平均的には 3-４日と見て下さい。
但し、一部の調査レポートでは、発注を受けた段階で内容更新をして納品をする場合もあります。
発注をする前のお問合せをお願いします。

注文の手続きはどのようになっていますか?

1)お客様からの御問い合わせをいただきます。
2)見積書やサンプルの提示をいたします。
3)お客様指定、もしくは弊社の発注書をメール添付にて発送してください。
4)データリソース社からレポート発行元の調査会社へ納品手配します。
5) 調査会社からお客様へ納品されます。最近は、pdfにてのメール納品が大半です。

お支払方法の方法はどのようになっていますか?

納品と同時にデータリソース社よりお客様へ請求書（必要に応じて納品書も）を発送いたします。
お客様よりデータリソース社へ（通常は円払い）の御振り込みをお願いします。
請求書は、納品日の日付で発行しますので、翌月最終営業日までの当社指定口座への振込みをお願いします。振込み手数料は御社負担にてお願いします。
お客様の御支払い条件が60日以上の場合は御相談ください。
尚、初めてのお取引先や個人の場合、前払いをお願いすることもあります。ご了承のほど、お願いします。

データリソース社はどのような会社ですか?

当社は、世界各国の主要調査会社・レポート出版社と提携し、世界各国の市場調査レポートや技術動向レポートなどを日本国内の企業・公官庁及び教育研究機関に提供しております。
世界各国の「市場・技術・法規制などの」実情を調査・収集される時には、データリソース社にご相談ください。
お客様の御要望にあったデータや情報を抽出する為のレポート紹介や調査のアドバイスも致します。

ワクチンアジュバント市場：製品（粒子、エマルジョン、病原体、サポニン）、投与経路（皮下、筋肉内）、疾患タイプ（感染症、癌）、用途（研究、商業）、用途分類別 - 2027年までの世界予測

サマリー

目次

Summary

Table of Contents

ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。

本レポートと同分野（抗生物薬）の最新刊レポート

MarketsandMarkets社の抗生物薬分野での最新刊レポート

本レポートと同じKEY WORD（cancer）の最新刊レポート

よくあるご質問

MarketsandMarkets社はどのような調査会社ですか?

調査レポートの納品までの日数はどの程度ですか?

注文の手続きはどのようになっていますか?

お支払方法の方法はどのようになっていますか?

データリソース社はどのような会社ですか?